Expression of the tumor suppressor miR-206 is associated with cellular proliferative inhibition and impairs invasion in ERα-positive endometrioid adenocarcinoma

Cancer Letters

Volumn 314, Issue 1, 2012, Pages 41-53

  Chen, Xiaoyue ^a   Yan, Qin ^a   Li, Shuangdi ^b   Zhou, Long ^a   Yang, Huajing ^a   Yang, Yixia ^b   Liu, Xuelian ^b   Wan, Xiaoping ^a  

^a SHANGHAI CHILDREN S HOSPITAL   (China)

^b SHANGHAI FIRST PEOPLE S HOSPITAL   (China)

Author keywords

Endometrial endometrioid adenocarcinoma (EEC); Estrogen receptor alpha (ER ); MicroRNA 206 (miR 206)

Indexed keywords

ESTROGEN RECEPTOR ALPHA; LUCIFERASE; MICRORNA; MICRORNA 206; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CANCER CELL CULTURE; CANCER INVASION; CARCINOGENESIS; CELL CYCLE ARREST; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; ENDOMETRIUM CARCINOMA; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; INHIBITION KINETICS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ADULT; CARCINOMA, ENDOMETRIOID; CELL LINE, TUMOR; CELL PROLIFERATION; ENDOMETRIAL NEOPLASMS; ESTROGEN RECEPTOR ALPHA; FEMALE; HUMANS; MICRORNAS; MIDDLE AGED; NEOPLASM INVASIVENESS;

EID: 82355191732     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2011.09.014     Document Type: Article

References (44)

1. Bokhman J.V. Two pathogenetic types of endometrial carcinoma. Gynecol. Oncol. 1983, 15:10-17.
2. Azueta A., Gatius S., Matias-Guiu X. Endometrioid carcinoma of the endometrium: pathologic and molecular features. Semin. Diagn. Pathol. 2010, 27:226-240.
3. Schouten L.J., Goldbohm R.A., van den Brandt P.A. Anthropometry, physical activity, and endometrial cancer risk: results from the Netherlands cohort study. Int. J. Gynecol. Cancer 2006, 16(Suppl 2):492.
4. K.J. Dedes, D. Wetterskog, A. Ashworth, S.B. Kaye, J.S. Reis-Filho, Emerging therapeutic targets in endometrial cancer. Nat. Rev. Clin. Oncol. (2011).
5. Kaaks R., Lukanova A., Kurzer M.S. Obesity, endogenous hormones, and endometrial cancer risk: a synthetic review. Cancer Epidemiol. Biomarkers Prev. 2002, 11:1531-1543.
6. Srijaipracharoen S., Tangjitgamol S., Tanvanich S., Manusirivithaya S., Khunnarong J., Thavaramara T., Leelahakorn S., Pataradool K. Expression of ER, PR, and Her-2/neu in endometrial cancer: a clinicopathological study. Asian Pac. J. Cancer Prevent. 2010, 11:215-220.
7. Andersson H., Helmestam M., Zebrowska A., Olovsson M., Brittebo E. Tamoxifen-induced adduct formation and cell stress in human endometrial glands. Drug Metab. Dispos. 2010, 38:200-207.
8. Adams B.D., Furneaux H., White B.A. The micro-ribonucleic acid (miRNA) miR-206 targets the human estrogen receptor-alpha (ERalpha) and represses ERalpha messenger RNA and protein expression in breast cancer cell lines. Mol. Endocrinol. 2007, 21:1132-1147.
9. Kondo N., Toyama T., Sugiura H., Fujii Y., Yamashita H. miR-206 Expression is down-regulated in estrogen receptor alpha-positive human breast cancer. Cancer Res. 2008, 68:5004-5008.
10. Ambros V. microRNAs: tiny regulators with great potential. Cell 2001, 107:823-826.
11. Li C., Feng Y., Coukos G., Zhang L. Therapeutic microRNA strategies in human cancer. AAPS J. 2009, 11:747-757.
12. Wu W., Lin Z., Zhuang Z., Liang X. Expression profile of mammalian microRNAs in endometrioid adenocarcinoma. Eur. J. Cancer Prev. 2009, 18:50-55.
13. Ratner E.S., Tuck D., Richter C., Nallur S., Patel R.M., Schultz V., Hui P., Schwartz P.E., Rutherford T.J., Weidhaas J.B. MicroRNA signatures differentiate uterine cancer tumor subtypes. Gynecol. Oncol. 2010, 118:251-257.
14. Cohn D.E., Fabbri M., Valeri N., Alder H., Ivanov I., Liu C.G., Croce C.M., Resnick K.E. Comprehensive miRNA profiling of surgically staged endometrial cancer. Am. J. Obstr. Gynecol. 2010, 202:656 e1-658 e1.
15. Creasman W. Revised FIGO staging for carcinoma of the endometrium. Int. J. Gynaecol. Obstet. 2009, 105:109.
16. Abu-Rustum N.R., Zhou Q., Iasonos A., Alektiar K.M., Leitao M.M., Chi D.S., Sonoda Y., Soslow R., Hensley M., Barakat R.R. The Revised 2009 FIGO Staging System for Endometrial Cancer: Should the 1988 FIGO Stages IA and IB Be Altered?. Int. J. Gynecol. Cancer 2010, 21:511-516.
17. He Y.Y., Cai B., Yang Y.X., Liu X.L., Wan X.P. Estrogenic G protein-coupled receptor 30 signaling is involved in regulation of endometrial carcinoma by promoting proliferation, invasion potential, and interleukin-6 secretion via the MEK/ERK mitogen-activated protein kinase pathway. Cancer Sci. 2009, 100:1051-1061.
18. Leivonen S.K., Makela R., Ostling P., Kohonen P., Haapa-Paananen S., Kleivi K., Enerly E., Aakula A., Hellstrom K., Sahlberg N., Kristensen V.N., Borresen-Dale A.L., Saviranta P., Perala M., Kallioniemi O. Protein lysate microarray analysis to identify microRNAs regulating estrogen receptor signaling in breast cancer cell lines. Oncogene 2009, 28:3926-3936.
19. Lebeau A., Grob T., Holst F., Seyedi-Fazlollahi N., Moch H., Terracciano L., Turzynski A., Choschzick M., Sauter G., Simon R. Oestrogen receptor gene (ESR1) amplification is frequent in endometrial carcinoma and its precursor lesions. J. Pathol. 2008, 216:151-157.
20. Jongen V., Briet J., de Jong R., ten Hoor K., Boezen M., van der Zee A., Nijman H., Hollema H. Expression of estrogen receptor-alpha and -beta and progesterone receptor-A and -B in a large cohort of patients with endometrioid endometrial cancer. Gynecol. Oncol. 2009, 112:537-542.
21. Tan D.S., Lambros M.B., Marchio C., Reis-Filho J.S. ESR1 amplification in endometrial carcinomas: hope or hyperbole?. J. Pathol. 2008, 216:271-274.
22. Bollig A., Miksicek R.J. An estrogen receptor-alpha splicing variant mediates both positive and negative effects on gene transcription. Mol. Endocrinol. 2000, 14:634-649.
23. Giacinti L., Claudio P.P., Lopez M., Giordano A. Epigenetic information and estrogen receptor alpha expression in breast cancer. Oncologist 2006, 11:1-8.
24. V. Pelekanou, M. Kampa, D. Gallo, G. Notas, M. Troullinaki, H. Duvillier, Y. Jacquot, E.N. Stathopoulos, E. Castanas, G. Leclercq, The estrogen receptor alpha-derived peptide ERalpha17p (P(295)-T(311)) exerts pro-apoptotic actions in breast cancer cells in vitro and in vivo, independently from their ERalpha status, Mol, Oncol, 5 (2011) 36-47.
25. M. Li, J. Li, X. Ding, M. He, S.Y. Cheng, microRNA and cancer. AAPS J. 12 (2010) 309-317.
26. Terao M., Fratelli M., Kurosaki M., Zanetti A., Guarnaccia V., Paroni G., Tsykin A., Lupi M., Gianni M., Goodall G.J., Garattini E. Induction of miR-21 by retinoic acid in estrogen receptor-positive breast carcinoma cells: biological correlates and molecular targets. J. Biol. Chem. 2011, 286:4027-4042.
27. Di Leva G., Gasparini P., Piovan C., Ngankeu A., Garofalo M., Taccioli C., Iorio M.V., Li M., Volinia S., Alder H., Nakamura T., Nuovo G., Liu Y., Nephew K.P., Croce C.M. MicroRNA cluster 221-222 and estrogen receptor alpha interactions in breast cancer. J. Natl. Cancer Inst. 2010, 102:706-721.
28. Liu W.H., Yeh S.H., Lu C.C., Yu S.L., Chen H.Y., Lin C.Y., Chen D.S., Chen P.J. MicroRNA-18a prevents estrogen receptor-alpha expression, promoting proliferation of hepatocellular carcinoma cells. Gastroenterology 2009, 136:683-693.
29. Zhou J., Song T., Gong S., Zhong M., Su G. microRNA regulation of the expression of the estrogen receptor in endometrial cancer. Mol. Med. Report 2010, 3:387-392.
30. Cheng C., Fu X., Alves P., Gerstein M. mRNA expression profiles show differential regulatory effects of microRNAs between estrogen receptor-positive and estrogen receptor-negative breast cancer. Genome Biol. 2009, 10:R90.
31. Klinge C.M. Estrogen Regulation of MicroRNA Expression. Curr. Genom. 2009, 10:169-183.
32. H. Dong, M. Paquette, A. Williams, R.T. Zoeller, M. Wade, C. Yauk, Thyroid hormone may regulate mRNA abundance in liver by acting on microRNAs, PLoS One 5 (2010) e12136.
33. Wang X., Ling C., Bai Y., Zhao J. MicroRNA-206 Is Associated With Invasion and Metastasis of Lung Cancer. Anat. Rec. (Hoboken) 2011, 294:88-92.
34. Miyachi M., Tsuchiya K., Yoshida H., Yagyu S., Kikuchi K., Misawa A., Iehara T., Hosoi H. Circulating muscle-specific microRNA, miR-206, as a potential diagnostic marker for rhabdomyosarcoma. Biochem. Biophys. Res. Commun. 2010, 400:89-93.
35. Chen J.F., Tao Y., Li J., Deng Z., Yan Z., Xiao X., Wang D.Z. microRNA-1 and microRNA-206 regulate skeletal muscle satellite cell proliferation and differentiation by repressing Pax7. J. Cell Biol. 2010, 190:867-879.
36. Shan Z.X., Lin Q.X., Deng C.Y., Zhu J.N., Mai L.P., Liu J.L., Fu Y.H., Liu X.Y., Li Y.X., Zhang Y.Y., Lin S.G., Yu X.Y. miR-1/miR-206 regulate Hsp60 expression contributing to glucose-mediated apoptosis in cardiomyocytes. FEBS Lett. 2010, 584:3592-3600.
37. Song G., Zhang Y., Wang L., notch3 MicroRNA-206 targets, apoptosis activates and inhibits tumor cell migration and focus formation. J. Biol. Chem. 2009, 284:31921-31927.
38. Adams B.D., Cowee D.M., White B.A. The role of miR-206 in the epidermal growth factor (EGF) induced repression of estrogen receptor-alpha (ERalpha) signaling and a luminal phenotype in MCF-7 breast cancer cells. Mol. Endocrinol. 2009, 23:1215-1230.
39. Aglund K., Rauvala M., Puistola U., Angstrom T., Turpeenniemi-Hujanen T., Zackrisson B., Stendahl U. Gelatinases A and B (MMP-2 and MMP-9) in endometrial cancer-MMP-9 correlates to the grade and the stage. Gynecol. Oncol. 2004, 94:699-704.
40. Talvensaari-Mattila A., Santala M., Soini Y., Turpeenniemi-Hujanen T. Prognostic value of matrix metalloproteinase-2 (MMP-2) expression in endometrial endometrioid adenocarcinoma. Anticancer Res. 2005, 25:4101-4105.
41. Liu H., Cao Y.D., Ye W.X., Sun Y.Y. Effect of microRNA-206 on cytoskeleton remodelling by downregulating Cdc42 in MDA-MB-231 cells. Tumori 2010, 96:751-755.
42. Soslow R.A. Endometrial carcinomas with ambiguous features. Semin Diagn Pathol 2010, 27:261-273.
43. Alektiar K.M., McKee A., Lin O., Venkatraman E., Zelefsky M.J., McKee B., Hoskins W.J., Barakat R.R. Is there a difference in outcome between stage I-II endometrial cancer of papillary serous/clear cell and endometrioid FIGO Grade 3 cancer?. Int. J. Radiat. Oncol. Biol. Phys. 2002, 54:79-85.
44. Zannoni G.F., Vellone V.G., Arena V., Prisco M.G., Scambia G., Carbone A., Gallo D. Does high-grade endometrioid carcinoma (grade 3 FIGO) belong to type I or type II endometrial cancer?. A clinical-pathological and immunohistochemical study, Virchows Arch. 2010, 457:27-34.